Fortress Biotech Inc.

News & Events

Press Releases

In The Media

1. Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

   GlobeNewswire MAY 30, 2025 10:47 AM EDT
   MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress&#...
   READ ARTICLE

2. Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

   GlobeNewswire MAY 15, 2025 4:05 PM EDT
   Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea i...
   READ ARTICLE

3. Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

   GlobeNewswire MAY 14, 2025 4:01 PM EDT
   Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emro...
   READ ARTICLE

4. Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

   GlobeNewswire MAY 13, 2025 4:15 PM EDT
   UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only a...
   READ ARTICLE

5. Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

   GlobeNewswire MAY 7, 2025 4:01 PM EDT
   SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey ...
   READ ARTICLE

6. Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

   GlobeNewswire MAY 7, 2025 8:00 AM EDT
   MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress&#...
   READ ARTICLE

7. Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

   GlobeNewswire APR 1, 2025 4:01 PM EDT
   SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ...
   READ ARTICLE

8. Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

   GlobeNewswire MAR 31, 2025 4:05 PM EDT
   Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, wi...
   READ ARTICLE

9. Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

   GlobeNewswire MAR 28, 2025 8:30 AM EDT
   WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpo...
   READ ARTICLE

10. Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

    GlobeNewswire MAR 26, 2025 4:01 PM EDT
    FDA Approval of Emrosi™ ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) ...
    READ ARTICLE